Eli Lilly’s obesity pill approved by FDA

The decision puts the drug in fierce competition against Novo Nordisk's new Wegovy pill as more people seek alternatives to GLP-1 injections ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

April 1, 2026 Check out STAT+

Sponsored By

Want some April Fools' Day fun? Check out today's STAT Mini themed crossword!

Maria Fabrizio for STAT Why an ovary syndrome may get a new name: Men seem to have PCOS, too The curious case of agreeing on a new term for polycystic ovary syndrome (PCOS), difficult to diagnose, hard to name when men share symptoms. By Annalisa Merelli Eli Lilly's obesity pill approved by FDA, setting up fierce competition with Novo Nordisk Consumers have already shown strong early interest in GLP-1 oral medications, which can be easily distributed and don't require cold storage. By Elaine Chen STAT+ | NIH director's invocation of Vannevar Bush's legacy to promote Trump science policies sparks pushback Bhattacharya invoked Bush's legacy at CPAC, but experts say NIH policies are diametrically opposed to Bush's 'Endless Frontier' vision. By Anil Oza Jenny Kane/AP Opinion: Medical marijuana should not be recommended for PTSD, anxiety, or depression 38 U.S. states and the District of Columbia allow PTSD patients to get medical marijuana cards. But cannabis does not help PTSD. By Kevin A. Sabet STAT+ | Can a psychedelic 'coach' make ketamine therapy even more effective? As ketamine treatment clinics have proliferated following FDA approval, some researchers think a pharmacological-only approach leaves benefits on the table. By O. Rose Broderick STAT+ | Government watchdog urges FDA to finalize guidance for advisory committee conflicts of interest The report arrives amid ongoing controversy over conflicts of interest at FDA advisory committees and concerns about undue industry influence. By Ed Silverman Adobe Opinion: Medicare is restricting care for 1 million Americans based on a faulty assumption. Congress must intervene CMS' decision to limit access to appropriate ostomy supplies will not reduce costs. It shifts them downstream. By Diego Schaps STAT+ | The biotech scorecard for the second quarter: 23 stock-moving events to watch Here's a look at top trial readouts and FDA approval decisions on drugs from Allogene Therapeutics, Cytokinetics, and other companies. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser